- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Jazz Pharmaceuticals (JAZZ) reported lower earnings and revenue for the 2016 second quarter and gave an outlook below Wall Street's expectations.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Jazz Pharma (JAZZ) stock coverage was started with an ‘outperform’ rating and $190 price target at BMO Capital.